There is a clinical situation that has become increasingly common and remains genuinely controversial: a man presents with low testosterone and textbook hypogonadal symptoms — fatigue, low libido, depression, reduced muscle mass, difficulty concentrating. His labs confirm the biochemistry. His symptoms are real. He wants treatment.
And then someone asks the uncomfortable question: is his testosterone low because something is wrong with his reproductive axis, or is it low because he is 80 pounds overweight, sleeps poorly, and has been taking opioids for chronic back pain for three years?
This is the functional hypogonadism question. It does not have a clean answer, and the clinical community has not fully agreed on one. What it does have is an increasingly nuanced framework that is changing how the most thoughtful practitioners approach it.
What Functional Hypogonadism Is
The British Society for Sexual Medicine defines testosterone deficiency as either organic or functional. Organic hypogonadism refers to conditions with proven dysfunction of the hypothalamic-pituitary-testicular (HPT) axis — Klinefelter syndrome, pituitary adenoma, prior radiation, orchitis, bilateral testicular failure. The axis is broken. The low testosterone reflects structural pathology.
Functional hypogonadism is different. Here, the HPT axis is intact but suppressed — not by disease of the axis itself, but by systemic conditions that impair its function. The pituitary still responds to GnRH. The testes still produce testosterone when stimulated. The problem is upstream: signals from the hypothalamus are being suppressed by metabolic or pharmacological interference.
The conditions most strongly associated with functional hypogonadism are:
Obesity and metabolic syndrome. Adipose tissue, particularly visceral fat, converts testosterone to estradiol through aromatization. More fat means more aromatase activity, which drives testosterone down and estradiol up — the resulting elevated estrogen exerts negative feedback on the hypothalamus, suppressing GnRH secretion. The result is a secondary hypogonadal pattern: low testosterone, low-to-normal LH. The heavier the man, the lower his testosterone tends to be.
Sleep apnea. The pulsatile secretion of testosterone is tightly linked to sleep architecture — specifically to slow-wave sleep. Obstructive sleep apnea fragments sleep and eliminates the restorative stages during which the largest testosterone pulses occur. Men with untreated severe sleep apnea can have markedly suppressed total testosterone despite normal HPT axis anatomy. Successful CPAP treatment has been shown in multiple studies to raise testosterone by clinically meaningful amounts.
Opioid-induced hypogonadism. Opioids suppress GnRH secretion directly at the hypothalamic level. This effect is dose-dependent, appears with both short and long-acting formulations, and is frequently underdiagnosed in men on chronic opioid therapy for pain. A man on sustained-release oxycodone who presents with fatigue and low libido should have his testosterone checked as a routine matter — and if it is low, the opioid is very likely contributing.
Type 2 diabetes and insulin resistance. The relationship between metabolic health and testosterone is bidirectional: low testosterone promotes insulin resistance and fat gain, and insulin resistance suppresses testosterone production. The causal arrow points both ways simultaneously, which is what makes this category clinically complex.
General poor health, acute illness, and certain medications (antipsychotics, anticonvulsants, anabolic steroids). Any state of significant physiological stress suppresses the HPT axis as a conserved biological response.
The Clinical Controversy
The controversy is this: should men with functional hypogonadism receive testosterone replacement therapy, or should they receive treatment for the underlying cause of their suppressed HPT axis?
The Endocrine Society and most major guidelines recommend lifestyle modification as first-line intervention for functional hypogonadism. This is physiologically sensible. Weight loss of 10% to 15% of body weight raises testosterone by approximately 50 to 100 ng/dL in obese men — a meaningful effect achieved without any pharmacological intervention. Exercise increases testosterone. CPAP treatment increases testosterone. Managing opioid therapy can partially restore the HPT axis. If the cause of suppression is reversible, reversing it is the right move.
The practical problem is execution. Telling a 250-pound man with fatigue, depression, and barely enough energy to get through the workday to “lose 10 to 15% of his body weight first and then we’ll see” is not a treatment plan most patients can successfully execute. Weight loss in the context of symptomatic hypogonadism is asking a man to run a race with lead weights on his feet, then promising to remove the weights if he finishes.
Some evidence suggests that TRT itself may help break this cycle: testosterone improves body composition, reduces fat mass, and improves insulin sensitivity, potentially creating metabolic conditions more conducive to the lifestyle changes the guidelines recommend. A short-term TRT trial for functional hypogonadism — not as a substitute for lifestyle intervention but as a metabolic intervention that enables it — is not an unreasonable clinical approach. The guidelines are cautious about this framing, but the science does not preclude it.
The Diagnostic Implications
Distinguishing organic from functional hypogonadism matters because it affects prognosis and treatment planning. Several features point toward functional rather than organic etiology:
- Low testosterone with low-to-normal LH and FSH in the context of obesity, metabolic syndrome, or opioid use
- Testosterone that fluctuates with changes in weight or health status
- Normal baseline testicular size and volume
- No history of testicular trauma, infection, or surgery
- No family history of hypogonadism or genetic syndromes
In functional hypogonadism, normalization of testosterone has been reported in studies of both surgical and behavioral weight loss — suggesting that the axis can recover when the suppressing condition is resolved. This recovery potential is not present in organic hypogonadism, where the structural lesion is permanent.
The BSSM guidelines identify obesity, type 2 diabetes, chronic kidney disease, COVID-19 infection, and its long-term manifestations as conditions in which functional TD is “more common” and treatment decisions should include lifestyle measures and a holistic review of the patient. This is a meaningful clinical statement: the guidelines are not saying “don’t treat these patients.” They are saying “treat the whole patient.”
Where Telehealth Fits
The functional hypogonadism question has a particular texture in the telehealth context. Telehealth platforms that specialize in TRT are, by design, more accessible to symptomatic men than traditional care pathways. This is mostly good — access to care has historically been a barrier for men who needed it.
But the functional hypogonadism population is also the population most likely to have treatable underlying causes that are not being addressed if the platform simply identifies low testosterone and prescribes testosterone. A platform that measures labs, identifies a secondary hypogonadal pattern in an obese patient, and initiates TRT without assessing sleep, opioid use, or metabolic status is not providing comprehensive care. It is providing symptom management.
The distinction matters to patient outcomes. Testosterone may improve the quality of life of a man with untreated severe sleep apnea — but a CPAP device will improve both his testosterone and his cardiovascular mortality. The clinically appropriate response accounts for both.
The platforms doing this well ask questions about sleep quality, medication history, and metabolic health alongside the testosterone labs. They treat testosterone deficiency as a symptom with a differential diagnosis, not a standalone condition with a single upstream cause. That is what personalized medicine looks like in practice.
The Synthesis
The functional hypogonadism debate is not really a debate about whether functional hypogonadism exists or whether it should be treated. It is a debate about sequencing, about whether lifestyle-first is genuinely actionable for a given patient, and about the degree to which TRT and lifestyle intervention can and should coexist.
The evidence supports lifestyle modification as effective when it is executed. The evidence also supports TRT as effective when it is appropriately managed. The most effective clinical approach appears to involve both, simultaneously, with regular reassessment of whether the underlying functional suppression has improved.
Testosterone is not a lifestyle replacement. But in functional hypogonadism, it may well be a lifestyle enabler. That is a more nuanced proposition than either the enthusiasts or the skeptics have typically been willing to defend, which is perhaps why the guidelines still describe it as a clinical judgement call.
Next up: Post 4 describes what good TRT actually looks like in practice — the baseline evaluation, the monitoring schedule, the 6-month check-in cycle, and how the telehealth model has changed access without changing the clinical essentials. Post 4: What Good TRT Looks Like.
